Patient Retention, Compliance Ads Should Be Larger Part Of DTC Spend, Consultant Says
This article was originally published in The Pink Sheet Daily
Increased compliance would improve product sales, DTC Perspectives CEO Ehrlich tells a conference on direct-to-consumer advertising in Boston. Pharma companies spent $3.48 bil. on DTC in 2003, 95% of which went toward branded ads.
You may also be interested in...
The agency pledges further review of its guidance on direct-to-consumer advertising. Broadcast ads for drugs and enforcement actions against repeat offenders could see more attention.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states